NASDAQ: SAVACassava Sciences Inc Stock
$1.44+0.04 (+2.86%)
Updated Apr 17, 2025
SAVA Price
$1.44
Fair Value Price
$2.76
Market Cap
$69.56M
52 Week Low
$1.15
52 Week High
$42.20
P/E
-2.72x
P/B
0.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$24.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$117M
Beta
1.36
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SAVA Overview
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SAVA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SAVA
Ranked#230 of 463
Ranked#230 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important SAVA news, forecast changes, insider trades & much more!
SAVA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SAVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SAVA ($1.44) is undervalued by 47.8% relative to our estimate of its Fair Value price of $2.76 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SAVA ($1.44) is significantly undervalued by 47.8% relative to our estimate of its Fair Value price of $2.76 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SAVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SAVA due diligence checks available for Premium users.
Valuation
SAVA fair value
Fair Value of SAVA stock based on Discounted Cash Flow (DCF)
Price
$1.44
Fair Value
$2.76
Undervalued by
47.80%
SAVA ($1.44) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SAVA ($1.44) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SAVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SAVA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.72x
Industry
-177.72x
Market
27.98x
SAVA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
4.05x
SAVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SAVA's financial health
Profit margin
Revenue
$0.0
Net Income
-$27.6M
Profit Margin
0%
SAVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$157.5M
Liabilities
$11.8M
Debt to equity
0.08
SAVA's short-term assets ($136.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SAVA's short-term assets ($136.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SAVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SAVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$61.3M
Investing
-$57.0k
Financing
$918.0k
SAVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SAVA vs Biotech Stocks
Cassava Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.